Tag: medical marijuana

Florida Bill To Make Medical Marijuana Cards Free For Military Veterans Passes House Unanimously

The Florida House of Representatives has unanimously approved a bill that would exempt military veterans from state registration fees for medical marijuana cards, allowing them to obtain the certifications for free.

After moving through committee earlier this month, the full chamber passed the legislation from Rep. Alex Andrade (R) in a 110-0 vote on Friday.

As originally filed, the measure would have made more significant changes to the state’s existing medical cannabis program, for example allowing home cultivation as well as reciprocity for out-of-state patients. But the House Health Professions and Programs Subcommittee replaced its language with a two-page substitute that instead would make only small changes to the medical program.

First, it would change how often patients need to renew their medical marijuana cards, from the current annual process to once every two years.

Second, it would waive the $75 registration and renewal fees for veterans, specifying that the state “may not charge a fee for the issuance, replacement, or renewal of an identification card for a qualified patient who is a veteran.”

On the floor, Rep. Daryl Campbell (D) thanked the sponsor for introducing the reform measure, saying “our veterans need medical marijuana cards often at rates higher than the general population, and it’s great that you are helping to ease the financial burden for them on this bill.”

Keep reading

Study: Medical Cannabis Improved PTSD Symptoms, Anxiety, and Quality of Life Over an 18-Month Period

The study followed 269 PTSD patients who were prescribed cannabis-based medicinal products (CBMPs) for at least 18 months. Conducted by researchers from Imperial College London, the Curaleaf Clinic, and King’s College London, the observational cohort study examined changes in PTSD-related symptoms, anxiety, sleep quality, and overall quality of life.

Patients experienced statistically significant improvements across all measured outcomes at each follow-up interval—1, 3, 6, 12, and 18 months. This included reductions in PTSD symptoms based on the Impact of Event Scale-Revised (IES-R), lower anxiety scores, better sleep quality, and enhanced health-related quality of life.

Notably, men were found to be less likely than women to report improvements in PTSD symptoms, with male gender associated with lower odds of symptom reduction.

Adverse events were reported by about one-quarter of participants. The most commonly reported side effects were insomnia (15.6%) and fatigue (14.9%).

“CBMPs [cannabis-based medicinal products] were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL[health-related quality of life] at up to 18 months”, states the study. “Although the study’s observational nature limits causal conclusions, these findings support further assessment of medical cannabis.”

Keep reading

North Dakota Governor Signs Bill To Legalize Medical Marijuana Edibles That Meet Certain Requirements

The governor of North Dakota has signed a bill into law legalizing select marijuana edibles for registered medical cannabis patients.

About a week after the measure from Rep. Steve Vetter (R) cleared the legislature, Gov. Kelly Armstrong (R) gave it final approval on Monday.

Under the newly enacted law, the state’s medical marijuana program will be expanded to permit the sale of cannabis edibles, which is defined as a “soft or hard lozenge in a geometric square shape into which a cannabinoid concentrate or the dried leaves or flowers of the plant of the genus cannabis is incorporated.”

While a fairly restrictive definition compared to many other legal states, advocates are encouraged by the development, as North Dakota patients were previously expressly prohibited from using cannabis products other than flower, tinctures, capsules and topical patches.

The new law requires edibles to contain no more than 5 milligrams of THC per serving in a package that can be up to 50 milligrams total.

In written testimony discussing the legislation, the sponsor emphasized that, “if this bill becomes law, it would be the most conservative edibles law in the nation.”

Keep reading

Nebraska Judge Allows Criminal Charges To Go Forward Against Notary Public For Voter-Passed Medical Marijuana Initiatives

The District Court of Hall County decided Tuesday to allow criminal charges against a notary public for “official misconduct” to proceed, overturning a lower court decision.

District Judge Andrew Butler, in a 10-page opinion, reversed a previous motion to quash against 24 counts of “official misconduct”—a Class II misdemeanor—against Jacy Todd of York, who was a notary for the successful ballot measures to legalize and regulate medical cannabis last year. Todd is believed to be the first notary criminally charged in this way.

Todd is accused of allegedly notarizing petition pages outside the presence of a petition circulator, Michael Egbert of Grand Island, on 24 different dates, each leading to a separate criminal charge. Todd has repeatedly denied all allegations.

Egbert admitted to using a phone book to illegally add voters to petition pages. He accepted a plea deal, reducing a Class IV felony charge to a Class I misdemeanor and $250 fine. Egbert said during a Lancaster County trial against the ballot measures that he has a mental condition that affects his memory.

Butler said he had to view the appeal from Hall County Attorney Marty Klein, who is working with the Nebraska Attorney General’s Office in the case, “in the light most favorable” to the State of Nebraska because Todd and his attorney have motioned to end the case.

More facts are needed, Butler argued, and the “extreme outcome” of a motion to quash should be “rare.”

“Granting the motion to quash was not appropriate at that time when considering the facts most favorable to the nonmoving party,” Butler wrote. “Further, and most importantly to the court, a notary public is a public servant that is subject to civil penalties and criminal penalties if warranted.”

Keep reading

Lawmakers In Slovenia Unveil Proposal To Legalize Marijuana For Medical And Scientific Use

Less than a year after voters in Slovenia approved a pair of marijuana ballot measures, lawmakers in the country have introduced a bill that would regulate cannabis specifically for medical and scientific use.

The measure, from the Freedom Movement (Gibanje Svoboda) and The Left (Levica) parties, would legalize cannabis extracts, plants and resin by removing the substances from Slovenia’s list of illegal drugs, according to local reports. THC, however, would remain prohibited unless used for medical or scientific reasons.

“Our goal is to protect patients and cannabis users from unverified products on the black market, enable uninterrupted medical cannabis supply to patients and address current legal shortcomings in the field of cannabis use for medical and scientific purposes,” the Freedom Movement said in a statement about the proposal, according to a report in N1.

Members of parliament “want to establish an efficient system that will take into account the existing competencies of the competent authorities, enable economic opportunities and clearly establish criteria for obtaining permits for growers, as well as researchers,” the party added.

Under the proposal, the Public Agency for Medicines and Medical Devices would be responsible for licensing and regulating the production and trade of medical marijuana. The Ministry of Health, meanwhile, would issue permits around marijuana used specifically for scientific purposes.

While the new proposal focuses only on medical marijuana, the Freedom Movement said it expects to take up regulation of cannabis for “limited personal use” by adults later this legislative session.

Keep reading

Medical cannabis shows potential to fight cancer, largest-ever study finds

The largest ever study investigating medical cannabis as a treatment for cancer, published this week in Frontiers in Oncology, found overwhelming scientific support for cannabis’s potential to treat cancer symptoms and potentially fight the course of the disease itself.

The intention of the analysis was to solidify agreement on cannabis’s potential as a cancer treatment, said Ryan Castle, research director at the Whole Health Oncology Institute and lead author of the study. Castle noted that it has been historically difficult to do so because marijuana is still federally considered an illegal Schedule I narcotic.

“Our goal was to determine the scientific consensus on the topic of medical cannabis, a field that has long been dominated by a war between cherrypicked studies,” Castle said.

The study was funded by Cancer Playbook, which works with the Whole House Oncology Institute to collect, analyze and share data on patient-reported outcomes.

While research restrictions on Schedule I substances severely hamper clinical research on cannabis in humans, there is a large body of observational studies on medical cannabis and cancer – as well as lab research – that looks at cannabis’s effect on tumors in test tubes and in animals. The analysis included as many of those studies as possible.

“In order to move beyond bias – conscious or not – it was essential to use a large-scale, radically inclusive methodology based on mathematical reasoning,” Castle said, adding: “We wanted to analyze not just a handful, but nearly every major medical cannabis study to find the actual points of scientific agreement.”

Castle’s study looked at more than 10,000 studies on cannabis and cancer, which he said is “10 times the sample size of the next largest study, which we believe helps make it a more conclusive review of the scientific consensus”.

To analyze the massive quantity of studies, Castle and his team used AI – specifically, the natural language processing technique known as “sentiment analysis”. This technique allowed the researchers to see how many studies had positive, neutral or negative views on cannabis’s ability to treat cancer and its symptoms by, for example, increasing appetite, decreasing inflammation or accelerating “apoptosis”, or the death of cancer cells.

Keep reading

North Carolina Lawmakers File Bill To Legalize Medical Marijuana For Patients With Debilitating Conditions

A new bill in the North Carolina House of Representatives would legalize medical marijuana for patients with a variety of specified conditions, including cancer, epilepsy, HIV/AIDS, Parkinson’s disease, PTSD, end-of-life care and other serious ailments.

The measure, HB 1011, was filed on Tuesday by Rep. Aisha Dew (D) and has been cosponsored by several other Democratic lawmakers.

The 28-page bill, titled the North Carolina Compassionate Care Act, is considerably more detailed than a separate Democrat-led medical marijuana bill introduced this week that would allow access only for patients enrolled in a “registered research study.”

Advocates have been awaiting House introduction of a comprehensive bill, especially since Senate President Phil Berger (R) said his chamber is deferring to the House to move first on medical marijuana reform this session.

“Glad to finally see a real medical cannabis bill get introduced,” Kevin Caldwell, Southeast legislative manager for the advocacy group Marijuana Policy Project, told Marijuana Moment in an email Wednesday.

The new bill, HB 1011, appears to be based largely on an earlier medical marijuana proposal from Sen. Bill Rabon (R), SB 3, filed in the 2023–2024 legislative session. That measure passed the Senate but failed to advance in the House due to an informal rule that requires a majority of the chamber’s GOP caucus to support a bill in order to bring it to the floor.

Caldwell at MPP said he would have liked to see the new House medical marijuana bill be sponsored by a Republican, which he reasoned would increase its chances of being heard in the GOP-controlled body. But he added that “legislators have known a medical bill has been in the works, and I hope they take this opportunity to provide relief to the tens of thousands of North Carolinians who are suffering from debilitating conditions.”

The new measure says in its findings section that “medical research has found that cannabis and cannabinoid compounds are effective at alleviating pain, nausea, and other symptoms associated with several debilitating medical conditions.” A majority of states and four of five U.S. territories have already legalized medical marijuana, it continues, and “North Carolina now takes similar action to preserve and enhance the health and welfare of its citizens.”

Under the proposal, the new medical cannabis program would be overseen by the state Department of Health and Human Services (DHHS).

Keep reading

Arkansas GOP Governor Vetoes Bill To Allow Drive-Thru Medical Marijuana Sales At Dispensaries And Ease Delivery Rules

The Republican governor of Arkansas has vetoed a bill that would have allowed medical cannabis sales at drive-thru windows at dispensaries, while also easing certain rules around marijuana delivery services for patients and caregivers.

After the legislation from Rep. Aaron Pilkington (R) narrowly advanced through the legislature, Gov. Sarah Huckabee Sanders (R) returned the measure with a veto message on Wednesday.

“This legislation would expand access to usable marijuana, therefore I am vetoing this legislation,” Sanders said.

Under the bill, licensed dispensaries would be have been authorized to “deliver usable marijuana to a qualified patient or designated caregiver via a drive-through window located at the dispensary,” the text says.

People would have needed to place an online order and pick up their products on the same day of the transaction.

The measure also would have revised existing statute to allow visitors to tour dispensaries in additional to cultivation facilities. And it would have made it so conventional medical cannabis deliveries could be handled by one employee, instead of the current minimum of two, if additional security measures were taken.

The governor didn’t address any of the specifics of the bill, instead simply voicing opposition to the idea of expanding access to cannabis.

Keep reading

CBD Helped Relieve Chronic Pain In More Than 98% Of Patients, Newly Published Study Finds

The marijuana component CBD can help patients manage chronic pain even at low dosages, making it “a promising alternative to conventional pain management strategies,” according to new research.

The peer-reviewed study, published in the journal Cureus, drew from responses to a survey posted on social media and in multiple medical clinics. Key findings, authors wrote, “are that the use of cannabinoids is positively associated with decreased chronic pain, even at low dosages (<100 mg).”

Most patients reported no side effects, while those who did reported only mild effects, the report says. No severe side effects were reported.

“These findings suggest that CBD may serve as a promising alternative to conventional pain management strategies,” the study concludes. “We believe these data point the way for new and continued avenues of research that can better optimize treatment regimens and help patients with chronic pain.”

The survey included 121 adults aged 21 and older who self-reported as having chronic pain, defined as pain lasting six months or longer. Questions involved demographics, patients’ perceptions of CBD’s effectiveness, dosage, frequency of use and side effects.

Authors wrote that they set out “to further explore this topic and add to the literature with the aim of asking chronic pain patients who use CBD for pain relief about their perceived benefits and side effects of CBD.”

Respondents were an average age of 37 years, and 61.2 percent were male. Most—100 people—said their pain had lasted two years or longer, while 21 said their pain had lasted 23 months or less.

As for causes of pain, the most common were arthritis (15.7 percent), disc herniation (14.9 percent), fibromyalgia (7.4 percent), headache or migraine (6.6 percent) and neuropathy (6.6 percent). Participants could select multiple responses.

Subjects were asked to rate their baseline level of chronic pain before CBD use on a scale from 1 to 10, as well as their pain level after beginning treatment.

“The average baseline level of chronic pain across participants before CBD was 5.4 ± 1.8,” the report says, “which decreased to 2.6 ± 1.7 (p < 0.0001, n = 121) after CBD, which is a decrease of 2.8 ± 1.7.”

Improvement was reported by 98.3 percent of subjects, while the remainder (1.7 percent, or two participants) reported no improvement at all. Three subjects “reported complete resolution of their baseline chronic pain after CBD,” according to the research.

Keep reading

Largest-Ever Analysis Of Medical Marijuana To Treat Cancer Symptoms Shows ‘Overwhelming Scientific Consensus’ On Benefits

Researchers this week published what they described as the “largest meta-analysis ever conducted on medical cannabis and its effects on cancer-related symptoms”, finding “overwhelming scientific consensus” on marijuana’s therapeutic effects.

The study, published in the journal Frontiers in Oncology, analyzed data from 10,641 peer-reviewed studies—what authors say is more than ten times the number in the next-largest review on the topic. Results “indicate a strong and growing consensus within the scientific community regarding the therapeutic benefits of cannabis,” it says, “particularly in the context of cancer.”

Given what the report calls a “scattered and heterogenous” state of research into the therapeutic potential of marijuana, authors aimed to “systematically assess the existing literature on medical cannabis, focusing on its therapeutic potential, safety profiles, and role in cancer treatment.”

“We expected controversy. What we found was overwhelming scientific consensus,” lead author Ryan Castle, head of research at Whole Health Oncology Institute, said in a statement. “This is one of the clearest, most dramatic validations of medical cannabis in cancer care that the scientific community has ever seen.”

The meta-analysis “showed that for every one study that showed cannabis was ineffective, there were three that showed it worked,” the Whole Health Oncology Institute said in press release. “That 3:1 ratio—especially in a field as rigorous as biomedical research—isn’t just unusual, it’s extraordinary.”

The institute added that the “level of consensus found here rivals or exceeds that for many [Food and Drug Administration]-approved medications.”

“The strong consensus supporting the therapeutic use of cannabis, particularly in the context of cancer, suggests that there is a substantial scientific basis for re-evaluating cannabis’ legal status and its classification as a Schedule I substance,” researchers said in the paper.

Keep reading